Every 10-Q that Sensus Healthcare Inc (SRTS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SRTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRTS filings page.
Sensus Healthcare, Inc. reported sharply weaker results for the quarter ended June 30, 2026. Revenue fell to $2.3 million from $7.3 million a year earlier, mainly due to fewer systems sold, no sales to a historically large U.S. customer, and more systems placed under Fair Deal and rental arrangements that recognize revenue over time.
Gross margin declined to 34.8%, and the company posted a quarterly net loss of $8.7 million, or $(0.53) per share. For the first six months, revenue was $5.7 million versus $15.7 million, with a net loss of $11.4 million. Management recorded a valuation allowance that eliminated the deferred tax asset, driving income tax expense of $5.7 million in the quarter and turning retained earnings into an accumulated deficit.
Cash, restricted cash, and equivalents declined to $15.2 million from $22.1 million as the business used $6.9 million in operating cash, while inventories increased to $18.5 million. The company has no debt outstanding and a new $15.0 million revolving credit facility with City National Bank of Florida, initially limiting borrowings to $2.0 million and secured by $2.2 million of restricted cash.
Sensus Healthcare (SRTS) reported Q3 2025 results showing softer demand and margin pressure. Revenue was $6.9 million, down 21.6% year over year, with gross profit of $2.7 million and a gross margin of 39.1% versus 59.1% a year ago. The quarter recorded a net loss of $0.9 million compared to net income of $1.2 million last year, driven by fewer unit sales and costs tied to a new placement program.
Operating expenses rose as the company increased R&D, marketing, and professional fees. Cash and cash equivalents were $24.5 million as of September 30, 2025, with accounts receivable at $9.3 million and inventories at $13.0 million. One U.S. customer accounted for 59% of quarterly revenue and 86% of accounts receivable. The company’s $15 million revolving credit facility had no borrowings outstanding; on September 26, 2025, the lender waived a default related to a minimum profitability covenant. Shares outstanding were 16,425,036 as of November 5, 2025.
Sensus Healthcare reported weakening sales and compressed margins in the quarter and year-to-date. Revenue was $7.3 million in Q2 and $15.7 million for the six months, declines of 20.7% and 21.1% versus prior-year periods driven primarily by fewer units sold to a large U.S. customer. Gross profit fell to $2.9 million in Q2 and $7.3 million YTD, and gross margin narrowed to 39.7% for the quarter (from 58.7%) and 46.5% YTD (from 60.8%).
Higher operating expenses outpaced revenue reductions: G&A, selling and marketing, and R&D all increased, with R&D up 127.8% YTD due to lobbying, added headcount and next-generation product development. The company recorded a net loss of $1.037 million in Q2 and a $3.609 million net loss for the six months, compared with net income in the prior-year periods.
Liquidity remains a stabilizing factor: cash and cash equivalents were $22.2 million and the amended revolving credit facility provides $15.0 million of available borrowing capacity with no outstanding borrowings, and the company was in compliance with credit covenants. Material risks disclosed include significant customer concentration (one U.S. customer represented 56% of Q2 revenue and 78% of receivables) and an ongoing DOJ inquiry for which potential costs cannot be estimated.